NCT05976763
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 27 versions: 26 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 238 → 242 locations
- Notable Eligibility criteria expanded, about 16 words
- Secondary endpoints: details revised at 6 of 6 entries
- Study description revised
- Site details revised at 31 of 238 sites
- Minor Site details revised at 3 of 238 sitesv25
- Minor Study sites: 237 to 238v24
- Notable Eligibility criteria shortened, about 6 words
- Study description expanded, about 65 words
Show 2 earlier versionsHide 2 earlier versions
- Minor Site details revised at 8 of 237 sitesv22
- Minor Study sites: 236 to 237v21
- Minor Trial sites expanded: 233 → 236 locationsv20
- Minor Study sites: 231 to 233v19
- Minor Study sites: 230 to 231v18
- Minor Study sites: 228 to 230v17
- Minor Study sites: 227 to 228v16
- Minor Site details revised at 2 of 227 sitesv15
- Minor Study sites: 218 to 227v14
- Minor Study sites: 213 to 218v13
- Minor Study sites: 209 to 213v12
- Minor Study sites: 204 to 209v11
- Notable Start date: Sep 8, 2023 to Oct 20, 2023
- Site contacts updated at 203 of 204 sites
- Minor Study sites: 178 to 204v9
- Minor Study sites: 155 to 178v8
- Minor Study sites: 138 to 155v7
- Minor Study sites: 104 to 138v6
- Minor Study sites: 62 to 104v5
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 62
- Notable Start date: Aug 8, 2023 to Sep 8, 2023v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (6)
Show 1 moreShow less
Arms and interventions
Patients receive zanubrutinib PO and rituximab IV on study. Patients undergo bone marrow biopsy and FDG PET/CT or CT throughout the trial. Patients may also undergo EDG and/or colonoscopy on study as clinically indicated. Patients may optionally undergo blood sample collection throughout the trial.
Patients receive zanubrutinib PO until first disease progression on study. Patients undergo CT or MRI or FDG PET/CT throughout the trial. Patients may optionally undergo blood sample collection throughout the trial.
Patients undergo observation until first disease progression and then receive zanubrutinib PO until second disease progression on study. Patients undergo CT or MRI or FDG PET/CT throughout the trial. Patients may optionally undergo blood sample collection throughout the trial.
Drugs: Zanubrutinib
Biologicals: Rituximab
Other: Patient Observation, Fludeoxyglucose F-18, Questionnaire Administration
Procedures: Bone Marrow Biopsy, Positron Emission Tomography, Computed Tomography, Magnetic Resonance Imaging, Esophagogastroduodenoscopy, Colonoscopy, Biospecimen Collection
Sites
242 sites in 1 country